re: Ann: Roger Corbett AO to be appointed to ...
Certainly a good appointment for HGN as his marketing skills should be big SP driver.
Corbett set to join HalcyGen board Eli Greenblat October 14, 2010 - 11:58AM
Former Woolworths boss and Fairfax Media chairman Roger Corbett is to be appointed a director of burgeoning pharmaceuticals company HalcyGen Pharmaceuticals Limited.
The company, which has a market capitalisation of $90 million, said this morning it will seek shareholder approval for Mr Corbett to be elected as a non-executive director of the company at its annual general meeting on November 17.
Mr Corbett was previously CEO of supermarket and retail giant Woolworths and is currently the chairman of Fairfax Media, one of Australia's largest diversified media companies. In 2005, Mr Corbett was appointed as a director of the Reserve Bank of Australia and in 2006, as a director of US-based Wal-Mart Stores, the world's largest retailer. In 2007, he was appointed deputy chairman of PrimeAg. Advertisement: Story continues below
Shares in HalcyGen rose 4.5 cents to 61.5 cents.
HalcyGen chief executive Roger Aston said: ?We are very privileged to have someone of Roger's calibre join our board.
"I also feel it is time now for HalcyGen to further build its retail capabilities, an area in which Roger brings tremendous wealth of experience from his work across many industries. HalcyGen is now poised for the next stage of its development and is looking to expand its marketing, branding and re-launching of products both in domestic and international markets.?
Mr Corbett said: ?It will be an honour to join the board of a company with such a rich and successful history, particularly stemming from the Mayne Pharma acquisition. I will be delighted to work with the HalcyGen board at a time of significant change and to be working with such a strong management team led by CEO Dr Roger Aston.?
Last year HalcyGen bought Mayne Pharma International (MPI) from Hospira Australia for $US15 million.
The division is one of the businesses Hospira bought when it purchased the publicly listed MPI in 2007. MPI, formerly known as FH Faulding & Co, is a specialist pharmaceutical company with an intellectual property portfolio built around the optimisation and delivery of oral dosage form drugs.
HalcyGen was listed on the Australian Securities Exchange in June 2007 after signing a global exclusive licence agreement with MPI to access product development and marketing rights for SUBA-Itraconazole, a synthetic broad-spectrum anti-fungal agent.
